Asthma Inhaler Names & Classes Stocked in India
Asthma inhaler classes and Indian brand names by category — SABA, ICS, ICS/LABA and reliever combinations — mapped to GINA 2024 treatment steps.
This covers what each class does pharmacologically, the commonly stocked asthma inhaler names within each in India, why GINA's 2024 guidance moved away from SABA-only reliever therapy, and what that shift means for a hospital pharmacy's stocking mix.
What is a SABA inhaler and which Indian brands fall in this class?
Short-acting beta-agonists like salbutamol provide rapid bronchodilation for acute symptom relief, working within minutes but offering no anti-inflammatory effect on the underlying airway disease. In India, salbutamol is stocked under brand names including Asthalin, Salbid and Asmanil, alongside generic salbutamol metered-dose inhalers.
SABA-only use as a reliever, without any background inhaled corticosteroid, is the pattern the 2024 GINA report specifically advises against for anyone beyond occasional, infrequent symptoms, because SABA-only reliance has been associated with worse long-term asthma outcomes across the population studied in GINA's evidence review.
A hospital stocking plain salbutamol as its only asthma reliever, without an ICS-containing option alongside it, is stocking to an older treatment model that GINA itself has since moved away from at every step of its 2024 strategy.
What does an ICS inhaler do and which brands are stocked in India?
Inhaled corticosteroids such as budesonide and fluticasone reduce airway inflammation over time as maintenance therapy, forming the pharmacological backbone of asthma control across every GINA treatment step from mild to severe disease. Budesonide is available in India under brands including Budecort and Pulmicort, prescribed and stocked in both inhaler and nebuliser forms.
ICS inhalers don't provide the rapid symptom relief a SABA does; their effect builds over days to weeks of regular use, which is a distinction that matters clinically because a patient using only an ICS inhaler during an acute exacerbation may not perceive immediate benefit and mistakenly conclude the drug isn't working.
Fluticasone-based ICS inhalers, stocked in India as Flohale and related brands, are the other widely used ICS alongside budesonide, and the two differ enough in relative potency per microgram that switching between them isn't a simple one-to-one substitution.
What is an ICS/LABA combination inhaler and which brands does India stock?
ICS/LABA combination inhalers pair an inhaled corticosteroid with a long-acting beta-agonist such as formoterol or salmeterol, delivering both anti-inflammatory control and sustained bronchodilation in a single device for step-up maintenance therapy. Budesonide/formoterol combinations are stocked in India under brands including Foracort and Formonide, while fluticasone-based combinations include Seretide and related fluticasone/salmeterol products.
Formoterol's faster onset compared to salmeterol is the specific pharmacological property that makes budesonide/formoterol combinations suitable for maintenance-and-reliever therapy, where the same inhaler covers both daily control and acute symptom relief. Salmeterol-based combinations lack that fast-onset property and are used strictly for maintenance, requiring a separate reliever inhaler alongside them.
A hospital pharmacy needs to distinguish these two sub-classes at the stocking level, since prescribing formoterol- and salmeterol-based combinations interchangeably ignores exactly the pharmacological difference that determines whether a patient can safely use one inhaler for both control and rescue.
Why did GINA 2024 change its recommendation away from SABA-only reliever use?
GINA's 2024 Global Strategy for Asthma Management and Prevention recommends ICS-containing reliever therapy, most commonly low-dose ICS/formoterol, over SABA-only reliever use at every treatment step, reflecting evidence that SABA-only reliance is associated with increased exacerbation risk and mortality across the population data GINA reviewed. This represents a structural shift in global asthma management guidance, not a minor adjustment.
The practical consequence for a hospital formulary is that stocking plain SABA inhalers as the sole reliever option no longer matches current guideline-concordant practice; ICS/formoterol combination inhalers now serve a dual maintenance-and-reliever role that GINA's own strategy document positions as preferred across most patients. That shift has direct implications for which asthma inhaler names a formulary committee prioritises when updating stock.
How should a hospital pharmacy structure its asthma inhaler stock?
A hospital pharmacy serving asthma patients needs representation across all four functional classes rather than concentrating stock in SABA alone. GINA's step-based approach moves patients between ICS-only, ICS/LABA and ICS/formoterol reliever regimens based on control status at each visit.
Stocking only the cheapest or most familiar asthma inhaler names within a class, without the full range a prescribing pulmonologist might select across steps, creates exactly the gap that sends a patient to an outside chemist mid-treatment.
Device technique also varies meaningfully across metered-dose inhalers, dry powder inhalers and nebuliser formulations, so a pharmacy's stock decisions should track which device type and which asthma inhaler names a hospital's own respiratory or paediatric department actually prescribes, rather than defaulting to whichever inhaler format is cheapest to stock.
What happens when a prescribed inhaler isn't available in-house?
An asthma prescription that isn't fillable inside the hospital sends the patient's family to an outside chemist, and for a chronic maintenance condition like asthma, that single walk-out often becomes the permanent pattern for every refill going forward, not just the first one. The hospital loses both the ongoing relationship and the visibility into whether the patient is actually adhering to the ICS-based maintenance regimen the treating doctor prescribed.
Reliable in-house stocking across all four inhaler classes is precisely the gap Medyzen's managed hospital pharmacy services are built to close, and our piece on prescription leakage covers what a chronic-condition prescription walking out the door costs a hospital over the full course of ongoing refills, not just the first fill. Our pharmacy inventory management guide covers the reorder discipline that keeps a multi-class inhaler stock like this from running short on any one step.
Sources
- 12024 GINA Report — Global Strategy for Asthma Management and Prevention — Global Initiative for Asthma
- 22024 Summary Guide for Asthma Management and Prevention — Global Initiative for Asthma
- 3Central Drugs Standard Control Organisation — Drugs and Cosmetics Act, 1940 and Rules, 1945
- 4World Health Organization — Chronic Respiratory Diseases — WHO
- 5National Pharmaceutical Pricing Authority — drug price control and formulation pricing, Government of India
This article is for informational purposes and is not a substitute for professional medical advice. It describes inhaler classes and brand availability for hospital stocking reference; it is not a treatment protocol. Consult the treating physician for any individual patient's inhaler regimen.
FAQ
Frequently asked questions
A reliever inhaler, historically a SABA and now often an ICS/formoterol combination under GINA 2024 guidance, treats acute symptoms rapidly. A controller inhaler, typically an ICS or ICS/LABA combination, is taken regularly regardless of symptoms to reduce underlying airway inflammation over time.
Yes, they are commonly prescribed together as separate inhalers when a patient needs both rapid symptom relief and ongoing anti-inflammatory maintenance, though the specific regimen and whether a combination inhaler is more appropriate is a decision for the treating clinician.
GINA's 2024 evidence review found SABA-only reliever use associated with higher exacerbation and mortality risk across the population studied compared with ICS-containing reliever regimens, prompting a global shift in guideline recommendations toward ICS/formoterol as the preferred reliever option.
Different manufacturers' budesonide/formoterol inhalers may vary in device type and delivered dose per actuation even when the active ingredients match, so switching between brands is a decision that should involve the prescribing clinician rather than an automatic pharmacy-level substitution.
Nebuliser formulations of drugs like budesonide and salbutamol deliver the same active ingredient in a different delivery format, generally used for patients, including young children, who can't coordinate metered-dose or dry powder inhaler technique effectively.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.